Come meet us
Our latest publications
Find all our latest news, press releases and scientific publications.
MSCopilot® interim results at EAN 2026
Ad Scientiam unveils positive 1-year interim longitudinal results for MSCopilot® at EAN 2026
At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.
June 29, 2026
4 scientific posters at AAN 2026
Ad Scientiam at AAN 2026: 4 scientific posters to anchor digital biomarkers in neurological practice
In Chicago, April 18-22, 2026, Ad Scientiam presented 4 scientific posters at the American Academy of Neurology, covering MSCopilot® in MS and ME&MG™ in generalized autoimmune myasthenia.
April 18, 2026
Ad Scientiam expands to the US
Ad Scientiam officially establishes presence in the United States
We announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA.
April 16, 2026
MuCopilot® at JSM 2025
JSM 2025 — MuCopilot®: optimizing cystic fibrosis monitoring through digital biomarkers
At the Cystic Fibrosis Scientific Days 2025, we presented MuCopilot®, our home monitoring tool based on digital biomarkers measured via smartphone.
March 9, 2026
MSCopilot® biomarkers and clinical assessments
MSCopilot® biomarkers reflect traditional clinical assessments
In Dubai in December 2025, we presented MS-DETECT data on the correlation between MSCopilot® digital biomarkers and traditional clinical assessments.
December 5, 2025
MS-DETECT at RASEN 2025
MS-DETECT: digital biomarkers and clinical scores correlation at RASEN
At RASEN in November 2025 in Seville, interim analysis of 243 patients demonstrates that MSCopilot® digital biomarkers significantly correlate with MSFC-4 and EDSS clinical scores.
November 18, 2025